Genmab stock holds steady as analysts stick to a moderate buy view

Genmab stock (ISIN DK0010272202) is currently trading in the mid-30 dollar range, with MarketBeat data showing that the sponsored ADR opened at 33.60 dollars on the latest trading day as of September 6, 2026.

Analysts back Genmab with moderate buy

According to consensus figures compiled by MarketBeat on September 6, 2026, thirteen research firms currently cover Genmab and assign the company an average recommendation of moderate buy.

The same overview reports that three of these analysts rate the shares as hold, nine as buy and one as strong buy, underlining a generally positive stance from the sell side toward Genmab’s earnings prospects and pipeline.

In terms of price expectations, MarketBeat cites an average twelve month target of 39.50 dollars for Genmab stock based on updates over the last year, implying upside of 5.90 dollars or about 17.6 percent compared with the recent opening level of 33.60 dollars as of September 6, 2026.

Stock performance and market context

The same MarketBeat snapshot notes that Genmab A/S Sponsored ADR on NASDAQ, ticker GMAB, opened at 33.60 dollars on Friday’s session, providing investors with a reference point for the current trading band as of September 6, 2026.

For investors in German speaking markets, the ADR listing in New York offers indirect exposure, with Genmab often mentioned alongside larger European biotech peers when sector reports cover antibody therapies and oncology pipelines.

The distance between the 33.60 dollar opening level and the average analyst target of 39.50 dollars highlights that the market has not fully priced in the consensus expectations yet; whether that gap closes will depend on upcoming data readouts and quarterly figures.

Pipeline and partnership focus

Genmab is known for its antibody-based therapies, most prominently the multiple myeloma treatment Darzalex and the subcutaneous formulation Darzalex Faspro, which are marketed globally by Johnson and Johnson under license from Genmab.

An article on drug patent expirations by Intuition Labs notes that Genmab’s issued United States patents covering daratumumab, the active ingredient in Darzalex and Darzalex Faspro, are expected to expire in 2029 and 2031 in the United States, while corresponding protections in Europe and Japan begin to expire in 2030, based on disclosures in Genmab’s Form 20-F for fiscal year 2024.

These timelines show that the company’s key royalty stream from daratumumab should remain protected for several more years, which is a central element when investors assess longer term cash flow and balance it against the risks of competition and future biosimilar entry.

Genmab stock and investor takeaway

With Genmab stock opening at 33.60 dollars on the latest session and analysts’ average twelve month target sitting at 39.50 dollars as of September 6, 2026, the shares trade at a discount to consensus expectations but still reflect substantial value already assigned to the existing product portfolio and pipeline.

For investors, the combination of a moderate buy consensus, a visible target price premium and multi year patent protection on core antibody assets underscores that upcoming clinical data and quarterly reports will be closely watched for confirmation of the growth story.